The Effect of Short-Term Vitamin D Supplementation on Calcium Status in Vitamin D Insufficient Renal Transplant Recipients at Risk of Hypercalcaemia by Lynch Cronin, Irene et al.
1 
 
 
The Effect of Short-Term Vitamin D Supplementation on Calcium Status in Vitamin D Insufficient 
Renal Transplant Recipients at Risk of Hypercalcaemia. 
Irene Lynch Cronin BSc 1,2, Fiona Byrne MSc 1,2, Ross Doyle MB, BAO, BCh 2 ,William D Fraser 
MD FRCP FRCPath 3,4, Allison Chipchase PhD FRCPath 4, Joseph A Eustace FRCPI 2,5   
1 Department of Clinical Nutrition and Dietetics, Cork University Hospital, Cork, Ireland  
2 Department of Renal Medicine, Cork University Hospital, Cork, Ireland  
3 University of East Anglia, Department of Medicine, Norwich, UK 
4 Norfolk and Norwich University Hospitals, Colney Lane, Norwich, UK 
5 HRB Clinical Research Facility, Cork, Ireland 
Corresponding author: Irene Lynch Cronin. Department of Clinical Nutrition and Dietetics. Cork 
University Hospital, Wilton, Cork. Ireland. Tel: 00353 214922169. Fax: 00353 214920143 
E-mail: Irene.Cronin@hse.ie 
Abstract Word Count: 271 
Manuscript Word Count: 3293 
Short Title: Vitamin D and calcium post-transplant 
Acknowledgements: The authors thank the renal clinical nurse specialists and phlebotomists of 
Cork University Hospital and the research nurses of the Clinical Research Facility for their 
assistance in collecting the blood samples.  
2 
 
Financial Disclosure: This work was supported by the HRB Clinical Research Facility, Cork, 
Ireland and the vitamin D supplements were provided free of charge by Shield Health, Dublin, 
Ireland. 
  
3 
 
The Effect of Short-Term Vitamin D Supplementation on Calcium Status in Vitamin D 
Insufficient Renal Transplant Recipients at risk of Hypercalcaemia.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
Objective: Vitamin D insufficiency is highly prevalent amongst renal transplant recipients and in 
observational studies is associated with adverse outcomes. Hypercalcaemia, usually due to 
persistent hyperparathyroidism, also commonly occurs in this population and often coexists with 
vitamin D insufficiency. However, concern that vitamin D supplementation might exacerbate the 
pre-existing hypercalcaemia often leads clinicians to avoid vitamin D supplementation in such 
patients. This feasibility study aimed to quantify the effect on serum calcium of short-term low- 
dose cholecalciferol supplementation in a group of renal transplant recipients with a recent history 
of serum calcium levels >10 mg/dL.  
Design: This was a two-week, single arm, open-label trial.  
Setting: Renal transplant follow-up clinic in an Irish University Hospital.  
Subjects: 18 vitamin D insufficient adult patients with a functioning renal allograft (eGFR > 30 
ml/min/1.73m2) and a recent history of serum calcium>10mg/dL. 
Intervention: Two weeks of treatment with 1000 IU cholecalciferol/day.  
Main Outcome Measure: Change in plasma ionized calcium and urine calcium:creatinine ratio 
at follow-up as compared to baseline.  
Results: The mean (sd) baseline 25 (OH) vitamin D (25 (OH) D) concentration was 15.9 (5.97) 
ng/mL and the mean (sd) baseline serum calcium was 10.50 (0.6) mg/dL. Following the 2-week 
intervention, median (IQR) change in serum calcium from baseline to follow-up was -0.08 (-3.6 
to 0.08) mg/dL, p=0.3. Mean (sd) ionized calcium decreased from 5.24 (0.32) mg/dL at baseline 
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to 5.16 (0.28) mg/dL, p= 0.05. The median (IQR) change in the urinary calcium:creatinine ratio 
was 0.001 (-0.026 to 0.299) mg/mg, p=0.88. The median (IQR) change in 25 (OH) D was 3.6 (2.9 
to 6.2) ng/mL, p<0.05.  
 
Conclusions: In vitamin D insufficient renal transplant recipients at risk of hypercalcaemia, low-
dose short-term oral cholecalciferol supplementation improves 25 (OH) D concentrations without 
exacerbating hypercalcaemia or increasing the urinary calcium:creatinine ratio.  
Keywords: Vitamin D, hypercalaemia, renal transplant  
 
  
5 
 
Introduction 
It is well established that there is a high prevalence of vitamin D insufficiency (up to 94%) 
among renal transplant recipients.1, 2 The reasons for this trend to insufficiency are several fold 
including recommendations to minimize sun exposure advising use of sunscreens with a high sun 
protection factor (SPF) due to increased risk of skin cancer among the renal transplant 
population, inadequate nutritional vitamin D supplementation both during dialysis and after 
transplantation, and an increased vitamin D catabolism due to immunosuppressive drugs.3  
These are compounded by the same risk factors that affect the general healthy population which 
contribute to vitamin D insufficiency such as dietary inadequacy, obesity, aging, skin 
pigmentation, seasonality and latitude, as well as concomitant medications that affect vitamin D 
metabolism.4  
Vitamin D receptors are found in an array of tissues and organs in the body including the 
intestine and bone, the brain, heart, skin, breast and other organs where vitamin D has an 
important role in muscle function, immunity, cellular growth and maturation in addition to its 
classical role in bone metabolism. It is now recognised that many extra-renal cell types express 
one-alpha hydroxylase with intracellular conversion of 25 (OH) D to 1,25 (OH)2 D which exerts 
its effects at cellular level, including cell proliferation, induction of apoptosis and cell 
differentiation in an autocrine/paracrine function.5 Increasingly, epidemiological studies are 
reporting an association between low 25 (OH) D status and various diseases including cancer of 
the breast, ovaries and colon as well as cardiovascular and infectious disease.6  
While the effect of improved vitamin D status on bone disease and other conditions in renal 
transplant recipients has not been established in large randomised studies, based on 
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epidemiological studies of bone health it appears prudent to avoid deficiency. Vitamin D status is 
also associated with a range of renal transplant outcomes. A recent observational study of 435 
stable long-term renal transplant recipients demonstrated that low 25 (OH) D is independently 
associated with a higher risk of all-cause mortality, with deficiency (<12 ng/mL) being 
independently and significantly associated with a faster annual decrease in renal function.7 
Filipov et al8 in a retrospective observational study showed that higher vitamin D status is 
associated with lower proteinuria in kidney transplant recipients.  
A concern regarding the use of vitamin D supplementation is the potential increase in enteric 
calcium and phosphate absorption. This is a particular concern as a substantial minority of renal 
transplants are mildly hypercalcaemic. There is a dearth of research examining the use of 
nutritional vitamin D supplementation in hypercalcaemic renal transplant recipients. 
Hypercalcaemia poses a potential risk for graft injury9, and may also contribute to soft-tissue and 
vascular calcification so normocalcaemia is a desired target in clinical practice. Existing 
international guidelines caution against supplementing with nutritional vitamin D in the setting 
of hypercalcaemia.10, 11 However, we believe that because in many cases the hypercalcemia is the 
result of residual post-transplant hyperparathyroidism, that cautious vitamin D supplementation 
will avoid the deleterious effects of vitamin D deficiency while being unlikely to exacerbate the 
PTH driven hypercalcemia. We therefore conducted the following study to quantify the short 
term safety of a daily low-dose nutritional vitamin D supplement in renal transplant recipients 
with a recent history of serum calcium > 10mg/dL. 
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Methods 
This study was a two-week prospective single-arm, open-label interventional feasibility study. 
Ethical approval to conduct the study was obtained from the Clinical Research Ethics Committee 
of the Cork Teaching Hospitals and informed consent was obtained from each patient. Between 
October 2014 and May 2015, adult patients attending the renal transplant follow-up clinic at 
Cork University Hospital (CUH) who met the inclusion/exclusion criteria (Table 1) were invited 
to participate in the study. Inclusion criteria included a tendency towards hypercalcaemia 
(described as uncorrected serum calcium > 10 mg/dL) within the 6 months prior to study 
commencement, combined with vitamin D insufficiency (25 (OH) D <30 ng/mL) as per available 
25 (OH) D levels over the same historical period. In the hospital transplant clinic, patients are 
routinely reviewed every 1-3 months, therefore reviewing the results available within the 
previous 6 months identified those patients who had a persistent serum calcium > 10 mg/dL and 
not merely an individual spike in serum calcium levels. Patients with an estimated glomerular 
filtration rate (eGFR) <30 ml/min/1.73m2 were excluded from participation. The study was 
conducted by the hospital renal dietitian. 
At baseline, an early-morning spot urine sample was collected, and analysed for a calcium: 
creatinine ratio (urine calcium (mg/L)/urine creatinine (mg/L). Blood samples were also taken at 
baseline for serum creatinine, eGFR, serum total calcium, ionized calcium, serum phosphate, 
serum iPTH and serum albumin, which were performed on a standard clinical chemistry 
analyzer. 25 (OH) D was analysed using the automated chemiluminescent immunoassay method 
(Architect i 1000SR System, Abbott). Separate samples were taken for 1,25 (OH)2 D and FGF23, 
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which were centrifuged, frozen and stored at – 800C until required for analysis. Samples were 
subsequently analysed for 1,25 (OH)2 D using the enzyme immunoassay (EIA) method 
(Immunodiagnostics Systems (IDS) Ltd., Boldon, Tyne and Wear, UK). Samples were also 
analysed for the C-terminal (180-251) amino acids of fibroblast growth factor-23 (FGF23) using 
the enzyme-linked immunosorbent assay (ELISA) method (Immutopics Int., San Clemente, CA, 
USA). 
Each subject met with the hospital renal dietitian who counselled them on maintaining their usual 
diet for the duration of the study to limit alterations in dietary intake of vitamin D or calcium 
from unduly influencing serum and urine levels. Time since transplantation, history of vitamin D 
supplement usage, consumption of vitamin D fortified foods, exposure to sunshine and usage of 
sunscreen was also recorded. Weight and height were recorded and BMI calculated. Each subject 
was provided with a 14 day supply of cholecalciferol supplements, and asked to take one 1000 
IU cholecalciferol supplement (soft gel capsule) per day for 14 days (Adult D3™ 1000 IU, Shield 
Health). At the end of the 14 day period, each subject repeated the spot urinary collection and 
blood analysis. Each patient met the renal dietitian at the end of the 14 day period, who checked 
for compliance with the supplements / dietary intake and questioned regarding timing of the 
early-morning spot sample. 
 
The central tendency, spread and distribution of variables was examined using standard tabular 
and graphical methods. The primary analysis was a paired comparison of change in ionized 
calcium and urine calcium: creatinine ratio at follow-up as compared to baseline. Analysis was 
conducted on SPSS v18 software (SPSS Inc., Chicago, IL, USA). 
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Results 
Patients attending the renal transplant follow-up clinic in Cork University Hospital over an eight-
week period (N=196) were screened using the inclusion/exclusion criteria. 45 eligible patients 
were identified and of these a total of 18 patients were enrolled into the study. 72 % were male 
(N=13). All were Caucasian. Our centre specific approach to renal allograft immunosuppression 
is been based on triple therapy using corticosteroids (with a steroid minimization policy in the 
last 8 years), Mycophenolate Mofetil and calcineurin inhibitors (predominantly cyclosporin 
before 2000 and tacrolimus thereafter). 
Table 2 shows the characteristics of the study group. 28 % participants were overweight with 22 
% of the subjects classified as obese (BMI>30kg/m2). This is of interest as obesity is linked with 
vitamin D deficiency due to storage of vitamin D in fat cells and consequent difficulty restoring 
serum levels. All of the patients were long-term renal transplant recipients (> 1 year since 
transplantation). The mean eGFR in the study group was 55.7 mL/min/1.73m2, corresponding to 
stage CKD 3T. Only 1 patient reported vitamin D supplement usage within the 6 months prior to 
the study, and in that individual case supplementation had discontinued 3 months prior to study 
enrolment. 
Table 3 compares the baseline and post-intervention serum and urinary parameters. All baseline 
albumin levels were > 4 g/dL therefore we reported uncorrected total serum calcium in addition to 
ionized calcium. Following the 2-week intervention median (IQR) change in serum calcium from 
baseline to follow-up was -0.08 (-3.6 to 0.08) mg/dL, p=0.3. There was no substantial change in 
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FGF23 (median change: -1.9 RU/mL). The median (IQR) change in the urinary calcium:creatinine 
ratio was 0.001 (-0.026 to 0.299) mg/mg, p=0.88 which was not significant. Mean (sd) baseline 
urine calcium: creatinine ratio was 0.16 (0.1) mg/mg which is below the threshold for 
hypercalciuria (>0.2 mg/mg). At baseline, PTH correlated with ionized calcium r=0.69, p=0.03. 
This was the only correlation of significance. 
Figures 1-3 illustrate the change in median values for 25 (OH) D; 1, 25 (OH)2 D, and ionized 
calcium respectively pre and post intervention. 
Discussion 
This study shows that a 1000 IU/day cholecalciferol supplement can improve vitamin D status in 
vitamin D insufficient renal transplant recipients with a history of serum calcium > 10 mg/dL 
without increasing serum calcium or causing hypercalciuria over a short-term period. 
Although the optimal vitamin D status in renal transplantation has yet to be defined, it has been 
suggested by the Endocrine Society Clinical Practice Guidelines that patients at risk of vitamin D 
deficiency should be screened and that vitamin D deficiency is defined as a 25 (OH) D below 20 
ng/mL and insufficiency as a 25 (OH) D of 21-29 ng/mL.12 Likewise the National Kidney 
Foundation guidelines defined vitamin D insufficiency as a serum 25 (OH) D <30ng/mL. 10 
Inclusion criteria for this study were vitamin D insufficiency/ deficiency combined with a recent 
history of a trend towards hypercalcaemia, defined in this study as a total serum calcium > 10 
mg/dL within the previous 6 months. In total, 69% of subjects were classified as a deficient 
vitamin D status (25 (OH) D <20 ng/mL) while 31% were insufficient (25 (OH) D of 21-30 
ng/mL). 
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A previous study conducted among the same population revealed that a high percentage of these 
patients have an inadequate dietary intake of vitamin D.13 In fact 93% of that study’s participants 
failed to achieve their recommended daily intake of vitamin D from diet. In addition, in the 
present study, only a minority (5%) reported usage of vitamin D fortified foods. Fortified foods 
such as fortified milk and yogurt would frequently be recommended to renal transplant recipients 
as a mode of increasing their calcium and/or vitamin D intake. However these patients may not 
have been actively encouraged to consume these foods due to concerns regarding their calcium 
concentrations. 
Significantly this present study found a high compliance to skin protection advice, with 94% 
participants reporting regular usage of sun protection factor preparations. It is known that a 
sunscreen with an SPF 30 reduces the skins production of vitamin D by more than 95%.14 
Patients would typically use a sunscreen with a very high protection index thereby extensively 
compromising this important route of vitamin D production. Additionally, it has been shown that 
at latitudes of 420N there is virtually no cutaneous vitamin D production during the months of 
November through February. Moreover, in Edmonton, Canada, which is at 520N -the same 
latitude as Cork (51.890N)- this period further extends from mid-October to April due to the 
increased zenith angle of the sun at this latitude.15 Our study was conducted between October 
and May which includes the winter season in Ireland. Stavroulopoulos et al 1 observed that the 
patients who had their vitamin D status checked in the Summer had the highest levels of 25 (OH) 
D (45±16 nmol/L) in comparison with those patients who had their 25 (OH) D levels checked in 
the Winter (24 ± 16 nmol/L). This was a UK study with a latitude of 52ºN, practically identical 
to that of  Cork.  
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Therefore, limited sunlight exposure due to season, latitude and time of day, further exacerbated 
by use of sunscreen and inadequate dietary vitamin D intake can give rise to vitamin D 
deficiency. 
A further factor contributing to altered levels of vitamin D metabolites is elevated levels of 
fibroblast growth factor 23 (FGF23). FGF23, a phosphaturic hormone secreted by osteocytes, is 
stimulated by phosphorus retention early in CKD and levels of FGF23 can remain elevated in the 
setting of renal transplantation. The effect of FGF23 is on its receptor Klotho which is found in 
both renal and parathyroid cells, and results in a decrease in the activation of 25 (OH) D in the 
kidney, and a decrease in PTH secretion by the parathyroid glands. FGF23 also induces the 
activity of the inactivating enzyme 24-alpha-hydroxylase in the kidney resulting in decreased 
circulating levels of both 25 (OH) D (which it converts to 24, 25 (OH)2 D) and 1,25 (OH)2 D 
(which it converts to 1,24,25 (OH)3 vitamin D). 72% of the subjects in the present study had an 
elevated baseline FGF23 (>100 RU/mL). Wolf et al16 carried out the first study investigating the 
effect of increased FGF23 on mortality and allograft survival in 984 long-term renal transplant 
patients, with a median transplant vintage of 72 months, and found that elevated FGF23 levels 
were independently associated with increased mortality and graft loss. The median (IQR) FGF23 
level at enrolment in that prospective study was 28 (20 to 43) RU/mL which is much lower than 
our results which describe a median (IQR) FGF23 of 150 (98-178) RU/mL. 
Additionally, immunosuppressants are also known to effect vitamin D metabolism, e.g. 
glucocorticoids directly increase 25 (OH) D and 1,25 (OH)2 D catabolism , and also indirectly via 
increasing FGF23 levels which impacts on 25 (OH) D and 1,25 (OH) 2 D levels as previously 
discussed.17 Animal studies have shown that cyclosporin and tacrolimus (calcineurin inhibitors) 
suppress the Vitamin D Receptor.18 
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Current guidelines for management of vitamin D status in the setting of renal transplantation are 
non-specific or rely on guidelines for non-transplanted CKD patients of the same renal function. 
The 2017 KDIGO CKD-MBD guideline update continues the 2009 recommendation to measure 
25 (OH) D levels, and in those patients with deficiency and insufficiency, treatment strategies 
recommended for the general population be implemented.19 Courebaisse et al 20 proposed a 
supplementation regimen based on their research, which compared the effect of cholecalciferol 
supplementation in normocalcaemic vitamin D deficient renal transplant recipients versus a non- 
supplemented control group and concluded that in the treatment group, 100,000 IU 
cholecalciferol every 2 weeks successfully and safely replete 25 (OH) D status. However, when 
the cholecalciferol dose was decreased to 100,000 IU every other month in the maintenance 
phase of the treated group, by month 12, serum 25 (OH) D concentrations decreased significantly 
and only remained above 30 ng/mL in 51% of patients. The investigators concluded that 
Holick’s recommendation for a maintenance dose of 100,000 IU cholecalciferol per month in 
patients with CKD is valid in the renal transplant group also. In the present study following only 
14 days of supplementation with a low dose of cholecalciferol (1000 IU/day), 25 (OH) D levels 
increased significantly from a mean of 15.9 ng/mL to 20.8 ng/mL(p <0.001) demonstrating the 
effectiveness of this level of supplementation.  
The incidence of hypercalcaemia amongst renal transplant populations varies amongst studies. 
Prevalence rates will vary between studies due to differences in definitions of hypercalcaemia 
and whether ionized, total serum or corrected serum calcium is used. Stavroulopoulos et al1 
found that 25% of the long-term transplant subjects in that study were hypercalcaemic, (defined 
as albumin-corrected calcium > 10.4 mg/dL), similarly our previous research demonstrated a 
prevalence of 24% (defined as albumin-corrected serum calcium > 10.5 mg/dL).13 When calcium 
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is measured as ionized calcium, higher levels are prevalent especially in the first year.21 In a 
prospective, observational study of 201 successfully transplanted patients, results indicated 
skeletal loss of calcium, mediated by high PTH levels is the most likely cause of post- 
transplantation hypercalcaemia.22 Hyperparathyroidism was present in our study with a mean 
(sd) baseline PTH of 1202 (678) pg/mL. Baseline PTH correlated with baseline ionized calcium, 
r=0.69, p=0.03 which supports the hyperparathyroidism-mediated hypercalcaemia mechanism. 
Ionized calcium decreased significantly following the intervention. This was an unexpected 
finding. It could be hypothesised that as a result of vitamin D supplementation, bone activity 
increased resulting in increased uptake of calcium by the bone. There was also a decrease in 
mean PTH at the end of the intervention although this was not significant. 
Despite the low levels of 25 (OH) D, baseline 1,25 (OH)2 D levels were in the reference range 
(mean 41.8 pg/mL). This finding is in agreement with Lomonte et al 23 who reported that the 
calcitriol levels in a selected cohort of renal transplant patients were normal and also reported no 
correlation between 25 (OH) D status and 1,25 (OH)2 D concentrations. Conversely a previous 
study showed that female gender, good renal function, high 25 (OH) D and high PTH levels were 
all independently associated with high calcitriol levels, although that study looked at the early 
post-transplant period.22 Mazzaferro et al 24 noted a lower impact of 25 (OH) D insufficiency on 
1,25 (OH)2 D levels in transplant recipients compared with CKD patients and also reported a 
positive relationship between calcium and 1,25(OH)2 D levels in a group of 136 renal transplant 
patients. They speculated that extra-renal hydroxylases contribute to the pool of serum 1,25 
(OH)2 D since renal production of calcitriol decreases in the setting of higher serum calcium 
levels. In the present study, mean 1,25 (OH)2 D levels increased significantly with 
cholecalciferol supplementation. This suggests that lower daily doses of cholecalciferol 
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supplementation may be more appropriate in this group versus mega-doses. It would be of 
interest to compare the effect of low versus high dose cholecalciferol supplementation on 1,25 
(OH)2 vitamin D and also on the concentrations of 24,25 (OH)2 vitamin D in this group. 
Our group profile was homogenous, with a majority of middle-aged men. It is known that 
women tend to have lower levels of 25 (OH) D compared with men.25 Although our group 
consisted entirely of Caucasians which would comprise the predominant ethnicity in the local 
population it is important to note that ethnic groups with dark skin-colour are more at risk of 
vitamin D deficiency as melanin is an effective natural sunscreen.4 Vitamin D status is also 
affected by aging as levels of 7-dehydrocholesterol decline with age, so there is less substrate for 
cutaneous vitamin D production. 4  
Limitations of the study include the small number of subjects and the short duration of the 
intervention. Despite this we see relatively uniform effects with some significant results being 
evident even in this small sample size. While the intervention period was not long enough to 
achieve adequate 25 (OH) D levels in all participants (dependent on their baseline 25 (OH) D 
levels), this initial safety study supports the feasibility and safety of conducting, with appropriate 
monitoring, a longer term interventional trial to quantify the risks and benefits of vitamin D 
supplementation in this population, particularly in relation to calcium metabolism. Such a trial is 
required as the long term safety and benefit of vitamin D supplementation in transplant patients 
with hypercalcaemia cannot be inferred from the current work yet it represents a potentially 
important and inexpensive intervention that may improve the bone and general health of such 
subjects.  
The patients that participated in this study discontinued the vitamin D supplementation after the 
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14-day trial, as this research needs to be extended before a general supplementation regimen can 
be implemented in this subgroup. However, patients who required additional repletion would 
have been individualised to a supplementation regimen and monitored closely by the renal 
dietitian and medical team. As a result of the study, a greater awareness of the prevalence of 25 
(OH) vitamin D inadequacy in this population has lead to routine monitoring of 25 (OH) D levels 
amongst our transplant patients and appropriate correction of same using a variety of nutritional 
vitamin D supplements. 
 
Practical Application 
Cautious daily dosing of cholecalciferol appears to safely restore 25 (OH) D concentrations in 
renal transplant patients at risk of hypercalcaemia in the short term. Further research is needed to 
establish long term safety in this sub-group. 
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Table 1. Inclusion and exclusion criteria 
Inclusion   Serum calcium > 10 mg/dL  
 25 (OH) D <30 ng/mL 
 >16 years of age  
 
Exclusion  eGFR < <30 ng/mL 
 Nutritional vitamin D supplementation within 3 months prior to study 
commencement. 
 Acute illness e.g. metastatic bone disease, sarcoidosis 
 Inability to comply with protocol  
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Table 2. Characteristics of study participants 
________________________________________________________________ 
Parameter      Value 
________________________________________________________________ 
Age (yr), mean (SD)      53 (13) 
Male gender, n (%)     13 (72) 
eGFR (mL/min/1.73m2), mean (SD)   55.7 (11.9) 
BMI (Kg/m2), mean (SD)    26.5 (4.9) 
Diabetes mellitus, n (%)    4 (22) 
Reported usage of fortified foods, n (%)  1 (5) 
Reported regular usage SPF, n (%)   17 (94) 
Time since transplant (yr), mean (SD)  7.6 (4.8) 
Reported use of vitamin D supplements, n (%) 1 (5) 
_________________________________________________________________ 
eGFR: estimated glomerular filtration rate; BMI: body mass index; SPF: sun protection factor 
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Table 3. Baseline and post-intervention serum and urinary parameters 
Parameter     Baseline mean (sd) Final mean (sd) p 
25(OH) vitamin D (ng/mL) [n=16]  15.9 (5.97)  20.8 (4.9)     <0.001 
1,25 (OH)2 vitamin D (pg/mL) [n=15] 41.8 (26.6)  49.4 (29.1)         0.05 
Calcium (mg/dL)    10.5 (0.6)  10.4 (0.5)          0.33 
Ionised calcium (mg/dL) [n=18]  5.2 (0.3)  5.16 (0.3)      0.05 
Phosphate (mg/dL)    2.6 (0.3)  2.7 (0.5)      0.08 
PTH (pg/mL)     1201.7 (677.7) 1126.3 (544.8)     0.74 
FGF23 (RU/mL)    143.2 (45.0)  141.6 (40.3)      0.90 
Urine Calcium:Creatinine ratio (mg/mg) 0.16 (0.1)  0.15 (0.10)      0.88 
Albumin (g/dL)    4.4 (0.28)  4.34 (0.24)      0.24 
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Figure 1. Median serum 25 (OH) D pre and post intervention 
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          Figure 2. Median serum 1,25 (OH)2 D pre and post intervention 
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        Figure 3. Median serum ionized calcium pre and post intervention. 
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